Storia in 5 fonti

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo's Datroway became the first to cross the FDA's finish line.

Raccontata da

pharmaceutical-technology.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 mesi fa

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

originale

Timeline cronologica

giovedì 21 maggio 2026·fiercepharma.com
Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med…
venerdì 22 maggio 2026·healio.com
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast…

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Confronto fonti

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Timeline cronologica

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of…

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Timeline cronologica

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of…

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer

Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer